ANT308 / Cambium Oncology - LARVOL DELTA

TARGETING VIP-RECEPTOR SIGNALING SELECTS A GUT MICROBIOME THAT SEPARATES GRAFT-VERSUS-LEUKEMIA (GVL) FROM GRAFT-VERSUS-HOST DISEASE (GVHD) IN ALLOGENEIC BONE MARROW TRANSPLANTATION (ALLO-BMT) (EBMT 2025) - "A potent peptide VIP-receptor antagonist (ANT308) was administered daily via subcutaneous injection for four weeks pre-transplant and/or four weeks post-transplant to evaluate its impact on microbiome composition and transplant outcomes... Microbiome transfer from VIP-KO mice to WT mice enhances anti-leukemic immunity, demonstrating the potential of a VIP-deficient microbiome to bolster tumor control. Pharmacologic inhibition of VIP signaling promotes microbiome shifts that mitigate GvHD while preserving GvL effects. These findings identify VIP-receptor signaling modulation as a promising strategy to separate GvHD from GvL, potentially improving outcomes in allo-BMT recipients."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

Seeking Investors: First-in-Class Immunotherapeutics for Cancer (PRNewswire) - "Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the company observes no toxicity-limiting dosages. In addition to their Fast-Track SBIR NIH grant recently being funded for $2.4M, they have received a significant investment from OEP Innovations of Taiwan....MULTIPLE PROOFS-OF-CONCEPT - Leukemia and Pancreatic Cancers: (1)Leukemia: ANT308 has shown strong single-agent anti-leukemia activity in 2 mouse models. (2) Pancreatic cancer: ANT308 has shown synergistic effects with anti-PD-1 checkpoint inhibitors in 3 pancreatic cancer models."

Financing • Preclinical • Leukemia • Pancreatic Cancer

Novel Therapies for AML and other Cancers (PRNewswire) - "Cambium Oncology and Orient Euro Pharma (OEP) announce a strategic partnership in which OEP has invested $5M in Cambium Oncology. This will accelerate the clinical development of Cambium Oncology's lead therapeutic candidate, ANT308, a FIRST-IN-CLASS vasoactive intestinal peptide (VIP) receptor antagonist designed to restore anti-cancer T-cell function. This investment is in addition to $2.4M recently received from the NIH. PROOF-OF-CONCEPT: ANT308 has shown strong single-agent anti-leukemia activity in two AML mouse models and synergistic effects with anti-PD-1 checkpoint inhibitors in three pancreatic cancer (PDAC) models."

Licensing / partnership • Pancreatic Ductal Adenocarcinoma